Exhibit 99.1
Schering-Plough Product Pipeline | ||
Worldwide Prescription Products | ||
| ||
Schering-Plough Corporation | ||
2000 Galloping Hill Road | August 2004 | |
Kenilworth, NJ 07033-0530 |
Phase II | ||
Adenosine 2a Receptor Antagonist | ||
Parkinson’s Disease | ||
4 | CCR5 Receptor Antagonist | |
HIV Infection | ||
SARASAR | ||
Leukemia | ||
Variety of Solid Tumors | ||
TEMODAR | ||
Variety of Tumors |
Phase III | ||
CLARINEX-D 12 Hour Seasonal Allergic Rhinitis | ||
CLARITIN/Singulair2 Seasonal Allergic Rhinitis | ||
4 | Garenoxacin Variety of Gram-Positive/Gram-Negative Bacterial Infections | |
INTEGRILIN | ||
4 | Early Acute Coronary Syndrome | |
NASONEX | ||
4 | Rhinosinusitis | |
PEG-INTRON Malignant Melanoma | ||
Posaconazole | ||
4 | Prophylaxis | |
REMICADE1 Psoriasis Ulcerative Colitis | ||
TEMODAR | ||
4 | First-Line Glioblastoma Multiforme |
NDA/BLA/PLA/HRD Filed | ||
ASMANEX (DPI) Asthma | ||
4 | Chronic Obstructive Pulmonary Disease (COPD) | |
4 | CLARINEX-D 24 Hour Seasonal Allergic Rhinitis | |
CLARINEX Syrup Chronic Urticaria Seasonal Allergic Rhinitis | ||
NASONEX | ||
4 | Polyposis | |
4 | Posaconazole Serious Fungal Infections | |
REMICADE1 | ||
4 | Psoriatic Arthritis |
4 Phase advance 4 Indication advance 1 International rights only 2 J.V. with Merck
Product Name | Market Size | Indications | U.S. Status | International Status | ||||
Adenosine 2a Receptor Antagonist Oral formulation | Prevalence in major world markets – 1.3 million Global market – $2.0 billion | Treatment of Parkinson’s disease | Phase II | Phase II | ||||
ASMANEX Anti-inflammatory steroid Oral inhaler | Oral inhaled steroid market: U.S. market – $1.0 billionInt’l market – $1.9 billion | Dry powder inhaler (DPI) – Asthma – COPD | Approvable 10/99 Phase III | Launched in UK 1/03 Filed in EU | ||||
CCR5 Receptor Antagonist Oral formulation | Market projections premature | Treatment of HIV infection | Phase II | Phase II | ||||
CLARINEX Nonsedating antihistamine Oral formulation | Oral antihistamine market: U.S. market – $4.6 billionInt’l market – $2.5 billion | Treatment of allergies: – CLARINEX Syrup – CLARINEX-D 24 Hour – CLARINEX-D 12 Hour | Approvable 10/01 NDA filed 4/04 Phase III | HRD approved 4/02 Filing not planned Phase III | ||||
CLARITIN/Singulair Nonsedating antihistamine Oral formulationleukotriene inhibitor | U.S. allergy market – $6.9 billion | Dual-action approach to treating allergies – Seasonal allergic rhinitis | J.V. with MRK Phase III/Evaluating clinical program | U.S. only | ||||
Garenoxacin Quinolone antibiotic Oral, injectable formulations | Worldwide antibiotic market – $25.5 billion | Treatment of a variety of gram-positive/gram-negative bacterial infections | Phase III | Phase III | ||||
INTEGRILIN Glycoprotein IIb/IIIa platelet aggregation inhibitor Injectable formulation | Total U.S. patients with ACS – 550 million | Treatment of early acute coronary syndrome (ACS) | Phase III | Primarily U.S. rights |
Product Name | Market Size | Indications | U.S. Status | International Status | ||||
NASONEX Anti-inflammatory steroid Nasal inhaler | Nasal inhaled steroid market: U.S. market – $2.3 billionInt’l market – $726 million | Treatment of allergies: – Polyposis – Rhinosinusitis | NDA filed 2/04 Phase III | Phase III Phase III | ||||
PEG-INTRON Long-acting antiviral/biological Injectable formulationresponse modifier | Worldwide interferon market – in excess of $1 billion | Cancer indications: – Malignant melanoma | Phase III | Phase III | ||||
Posaconazole Triazole antifungal Oral formulation | Worldwide antifungal market – in excess of $4.0 billion | – Treatment of serious fungal infections – Prophylactic treatment of serious fungal infections | NDA filed 5/04 Phase III | Filed in EU Phase III | ||||
REMICADE Monoclonal antibody Injectable formulation | Prevalence in int’l markets: Rheumatoid arthritis – 4 million Psoriasis – 6.3 millionPsoriatic arthritis – 650,000 Ulcerative colitis – 200,000 | Treatment of inflammatory diseases: – Psoriatic arthritis– Psoriasis – Ulcerative colitis | International only | CHMP recomm. app. 7/04 Phase III Phase III | ||||
SARASAR Farnesyl transferase inhibitor Oral formulation | Market projections premature | Treatment of cancer: – Leukemia – Variety of solid tumors | Phase II Phase II | Phase II Phase II | ||||
TEMODAR Cytotoxic chemotherapeutic agent Oral formulation | Alkylating agent market: U.S. market – $192 million Int’l market – $141 million | – First-line glioblastoma multiforme – Treatment of a variety of tumors | Phase III Early Phase | Phase III Early Phase |
Pipeline Updates / August 2004
Phase II
Pure Anti-Estrogen
CCR5 Receptor Antagonistfor HIV infection has advanced to Phase II on theProduct Pipeline.
Phase III
ASMANEX (MDI)
Garenoxacin
The following compounds or indications have advanced to Phase III on theProduct Pipeline:INTEGRILINfor early acute coronary syndrome,Posaconazolefor prophylactic treatment of serious fungal infections andTEMODARfor first-line glioblastoma multiforme.
NDA/HRD Filed
International regulatory submissions have been accepted as filed for the following compounds:REMICADEfor psoriatic arthritis,ASMANEX DPIfor COPD andPosaconazolefor serious fungal infections.
Note:
CLARINEX-D 12 Houris listed in Phase III on theProduct Pipeline. As previously reported, based on an analysis of an October 2001 “approvable” letter, SGP has determined that it intends to reformulate the product and seek approval for a new version with improved stability.
Recent Approvals
VYTORIN2 (ezetimibe/simvastatin)
Cholesterol lowering [U.S. 7/04, Germany, Mexico 4/04]
REMICADE1
Early rheumatoid arthritis [EU 6/04]
REMICADE1
Maintenance of fistulizing Crohn’s disease [EU 10/03]
PEG-INTRON REDIPEN
Hepatitis C [U.S. 10/03]
REBETOLoral solution
Pediatric use [U.S. 7/03]
REMICADE1
Ankylosing spondylitis [EU 5/03]
CAELYX1
Metastatic breast cancer [EU 1/03]
1 International rights only 2 J.V. with Merck
The SGPProduct Pipelineis solely intended to provide to investors general information regarding Schering-Plough products in development and, for this reason, the information is not represented to be complete. Due to market factors and the nature of the development and approval process, the information – including the status of these products – is subject to change.
“International Status” does not necessarily imply that the company will be marketing the compound in all major countries.
The trademarks indicated by CAPITAL LETTERS are the property of, licensed to, promoted or distributed by Schering-Plough, its subsidiaries or related companies.